Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid drag
ET Intelligence Group: Pharmaceuticals and healthcare companies are set for a mixed March-quarter. Hospital chains are expected to deliver steady growth while generic drugmakers face pressure from the absence of Revlimid-related sales and pricing headwinds. Lupin is expected to deliver strong growth in revenue, margin and profit, while Divi's is likely to benefit from improving contract development demand and operating…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
